Venetoclax: Another Oral Therapy Option for Patients With CLL

Pharmacy Today
doi 10.1016/j.ptdy.2016.05.016
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn84 - Total Cost of Care and Budget Impact for Patients With CLL Treated With Venetoclax

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

An Undetectable Pb MRD Status Should Be the Therapeutic Goal With Venetoclax Therapy in Relapsed/ Refractory CLL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Venetoclax–Obinutuzumab Elicits High Response Rates in CLL

Cancer Discovery
Oncology
2019English

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Biclonal IGHV -4-34 Variant Hairy Cell Leukemia and CLL - Successful Treatment With Ibrutinib and Venetoclax

American Journal of Hematology
Hematology
2018English

Clinical Benefit of Antisense Therapy in a Phase III Trial in Patients With CLL

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2007English

Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease

Archives of Internal Medicine
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy